Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
WASHINGTON, May 31, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will hold its 2012 Annual Meeting of Stockholders on Thursday, June 14, 2012, in Washington, D.C. The record date for the Annual Meeting is April 20, 2012. Only stockholders of record as of the close of business on April 20, 2012 may vote at the meeting or any adjournment thereof. Vanda's proxy statement and annual report are available at www.proxyvote.com and includes the time and location of the Annual Meeting, as well as a description of the matters to be considered.
ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.
Company Contact:
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(202) 734-3400
cristina.murphy@vandapharma.com
SOURCE Vanda Pharmaceuticals Inc.
RELATED LINKS
http://www.vandapharma.com
More by this Source
Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
Jun 17, 2013, 19:00 ET
Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
Jun 05, 2013, 21:00 ET
Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
May 31, 2013, 16:00 ET
Featured Video
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.




